In recent years, immunotherapy has gradually moved from the back line to the front line, from advanced to early patients.
In recent years, immunotherapy has gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.